{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:11:00Z","timestamp":1793329860717,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2314-B-182A-088"],"award-info":[{"award-number":["111-2314-B-182A-088"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2314-B-182A-086"],"award-info":[{"award-number":["111-2314-B-182A-086"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3M0761-2"],"award-info":[{"award-number":["CMRPG3M0761-2"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CMRPG3N0721-2"],"award-info":[{"award-number":["CMRPG3N0721-2"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["OMRPG3C0018"],"award-info":[{"award-number":["OMRPG3C0018"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yushan Young Fellow Program from Ministry of Education.","award":["NTU-112V1402-5"],"award-info":[{"award-number":["NTU-112V1402-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-026-02638-0","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:12:25Z","timestamp":1769217145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression through disrupted ribosome biogenesis"],"prefix":"10.1007","volume":"104","author":[{"given":"Chiao-Yun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Shine","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Hui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby Yun-Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-9645","authenticated-orcid":false,"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"2638_CR1","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/IGC.0000000000000289","volume":"24","author":"A Okamoto","year":"2014","unstructured":"Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, Takano M, Takano T, Susumu N, Aoki D et al (2014) Gynecologic cancer intergroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer 24:S20-25","journal-title":"Int J Gynecol Cancer"},{"key":"2638_CR2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jfma.2019.11.018","volume":"119","author":"HJ Huang","year":"2020","unstructured":"Huang HJ, Yang LY, Tung HJ, Ku FC, Wu RC, Tang YH, Chang WY, Jung SM, Wang CC, Lin CT et al (2020) Management and clinical outcomes of patients with recurrent\/progressive ovarian clear cell carcinoma. J Formos Med Assoc 119:793\u2013804. https:\/\/doi.org\/10.1016\/j.jfma.2019.11.018","journal-title":"J Formos Med Assoc"},{"key":"2638_CR3","doi-asserted-by":"crossref","unstructured":"Tan DSP RT, Barrie C, et al. (2014) Analysis of outcomes in patients (pts) with recurrent ovarian clear cell carcinoma (ROCCC): time to rethink our approach to treatment. J Clin Oncol 32 (15_suppl): 5548","DOI":"10.1200\/jco.2014.32.15_suppl.5548"},{"key":"2638_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s12885-021-08233-5","volume":"21","author":"N Lapke","year":"2021","unstructured":"Lapke N, Chen CH, Chang TC, Chao A, Lu YJ, Lai CH, Tan KT, Chen HC, Lu HY, Chen SJ (2021) Genetic alterations and their therapeutic implications in epithelial ovarian cancer. BMC Cancer 21:499","journal-title":"BMC Cancer"},{"key":"2638_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jfma.2017.03.007","volume":"117","author":"FC Ku","year":"2018","unstructured":"Ku FC, Wu RC, Yang LY, Tang YH, Chang WY, Yang JE, Wang CC, Jung SM, Lin CT, Chang TC et al (2018) Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: results from a single-center Taiwanese study. J Formos Med Assoc 117:117\u2013125. https:\/\/doi.org\/10.1016\/j.jfma.2017.03.007","journal-title":"J Formos Med Assoc"},{"key":"2638_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2011.01.005","volume":"121","author":"MS Anglesio","year":"2011","unstructured":"Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium S (2011) Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium, June 24th, 2010. Gynecol Oncol 121:407\u2013415. https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.005","journal-title":"Gynecol Oncol"},{"key":"2638_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2017.08.004","volume":"147","author":"KE Oliver","year":"2017","unstructured":"Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA et al (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG oncology\/gynecologic oncology group experience. Gynecol Oncol 147:243\u2013249. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.004","journal-title":"Gynecol Oncol"},{"key":"2638_CR8","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-21-3817","volume":"28","author":"KL Bolton","year":"2022","unstructured":"Bolton KL, Chen D, Corona de la Fuente R, Fu Z, Murali R, Kobel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ et al (2022) Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res 28:4947\u20134956","journal-title":"Clin Cancer Res"},{"key":"2638_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih IeM et al (2015) ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov 5:752\u2013767. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0849","journal-title":"Cancer Discov"},{"key":"2638_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare7030094","author":"T Amano","year":"2019","unstructured":"Amano T, Chano T, Yoshino F, Kimura F, Murakami T (2019) Current position of the molecular therapeutic targets for ovarian clear cell carcinoma: a literature review. Healthcare. https:\/\/doi.org\/10.3390\/healthcare7030094","journal-title":"Healthcare"},{"key":"2638_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/pcmedi\/pbaa030","volume":"3","author":"P Zhou","year":"2020","unstructured":"Zhou P, Wang J, Mishail D, Wang CY (2020) Recent advancements in PARP inhibitors-based targeted cancer therapy. Precis Clin Med 3:187\u2013201","journal-title":"Precis Clin Med"},{"key":"2638_CR12","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1158\/1078-0432.CCR-17-2186","volume":"23","author":"EC Kohn","year":"2017","unstructured":"Kohn EC, Lee JM, Ivy SP (2017) The HRD decision-which PARP inhibitor to use for whom and when. Clin Cancer Res 23:7155\u20137157","journal-title":"Clin Cancer Res"},{"key":"2638_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"2638_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","volume":"166","author":"MM Hardesty","year":"2022","unstructured":"Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Keeton EK, Wang P, Gupta D, Clements A et al (2022) OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 166:219\u2013229. https:\/\/doi.org\/10.1016\/j.ygyno.2022.05.020","journal-title":"Gynecol Oncol"},{"key":"2638_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2021.06.032","volume":"162","author":"FJ Backes","year":"2021","unstructured":"Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM et al (2021) Phase i evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 162:619\u2013625. https:\/\/doi.org\/10.1016\/j.ygyno.2021.06.032","journal-title":"Gynecol Oncol"},{"key":"2638_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","volume":"42","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas ME, Habra MA (2016) Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47\u201355","journal-title":"Cancer Treat Rev"},{"key":"2638_CR17","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.7150\/jca.50292","volume":"12","author":"J Ye","year":"2021","unstructured":"Ye J, Qi L, Liang J, Zong K, Liu W, Li R, Feng R, Zhai W (2021) Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT. J Cancer 12:3548\u20133557","journal-title":"J Cancer"},{"key":"2638_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I et al (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386:437\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa2108330","journal-title":"N Engl J Med"},{"key":"2638_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115869","author":"N Kawahara","year":"2021","unstructured":"Kawahara N, Yamada Y, Kobayashi H (2021) CCNE1 is a putative therapeutic target for ARID1A-mutated ovarian clear cell carcinoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22115869","journal-title":"Int J Mol Sci"},{"key":"2638_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122950","author":"V Pacheco-Barcia","year":"2022","unstructured":"Pacheco-Barcia V, Munoz A, Castro E, Ballesteros AI, Marquina G, Gonzalez-Diaz I, Colomer R, Romero-Laorden N (2022) The homologous recombination deficiency scar in advanced cancer: agnostic targeting of damaged DNA repair. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14122950","journal-title":"Cancers (Basel)"},{"key":"2638_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ebiom.2019.11.017","volume":"50","author":"TZ Tan","year":"2019","unstructured":"Tan TZ, Ye J, Yee CV, Lim D, Ngoi NYL, Tan DSP, Huang RY (2019) Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EBioMedicine 50:203\u2013210","journal-title":"EBioMedicine"},{"key":"2638_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ygyno.2014.05.009","volume":"134","author":"MM Shah","year":"2014","unstructured":"Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN (2014) An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 134:331\u2013337","journal-title":"Gynecol Oncol"},{"key":"2638_CR23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/jclinpath-2014-202430","volume":"67","author":"AL Kwok","year":"2014","unstructured":"Kwok AL, Wong OG, Wong ES, Tsun OK, Chan KK, Cheung AN (2014) Caution over use of ES2 as a model of ovarian clear cell carcinoma. J Clin Pathol 67:921\u2013922","journal-title":"J Clin Pathol"},{"key":"2638_CR24","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","volume":"15","author":"S Mabuchi","year":"2009","unstructured":"Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ et al (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15:5404\u20135413. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0365","journal-title":"Clin Cancer Res"},{"key":"2638_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00109-018-1699-5","volume":"96","author":"A Chao","year":"2018","unstructured":"Chao A, Lin CY, Wu RC, Lee YS, Lee LY, Tsai CL, Yang LY, Liu H, Chen SJ, Wang TH et al (2018) The combination of everolimus and terameprocol exerts synergistic antiproliferative effects in endometrial cancer: molecular role of insulin-like growth factor binding protein 2. J Mol Med (Berl) 96:1251\u20131266. https:\/\/doi.org\/10.1007\/s00109-018-1699-5","journal-title":"J Mol Med (Berl)"},{"key":"2638_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235962","author":"CY Lin","year":"2021","unstructured":"Lin CY, Wu RC, Huang CY, Lai CH, Chao AS, Li HP, Tsai CL, Kuek EJ, Hsu CL, Chao A (2021) A patient-derived xenograft model of dedifferentiated endometrial carcinoma: a proof-of-concept study for the identification of new molecularly informed treatment approaches. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13235962","journal-title":"Cancers (Basel)"},{"key":"2638_CR27","doi-asserted-by":"publisher","first-page":"37080","DOI":"10.18632\/oncotarget.26354","volume":"9","author":"K Sun","year":"2018","unstructured":"Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J (2018) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9:37080\u201337096","journal-title":"Oncotarget"},{"key":"2638_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H et al (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25:838\u2013849. https:\/\/doi.org\/10.1038\/s41591-019-0422-6","journal-title":"Nat Med"},{"key":"2638_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174405","author":"V Bezrookove","year":"2021","unstructured":"Bezrookove V, Patino JM, Nosrati M, Desprez PY, McAllister S, Soroceanu L, Baron A, Osorio R, Kashani-Sabet M, Dar AA (2021) Niraparib suppresses cholangiocarcinoma tumor growth by inducing oxidative and replication stress. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13174405","journal-title":"Cancers (Basel)"},{"key":"2638_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.666815","volume":"11","author":"OGW Wong","year":"2021","unstructured":"Wong OGW, Li J, Cheung ANY (2021) Targeting DNA damage response pathway in ovarian clear cell carcinoma. Front Oncol 11","journal-title":"Front Oncol"},{"key":"2638_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.07.002","volume":"203","author":"MH Jin","year":"2019","unstructured":"Jin MH, Oh DY (2019) ATM in DNA repair in cancer. Pharmacol Ther 203","journal-title":"Pharmacol Ther"},{"key":"2638_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-292","volume":"14","author":"T Di Palma","year":"2014","unstructured":"Di Palma T, Lucci V, de Cristofaro T, Filippone MG, Zannini M (2014) A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells. BMC Cancer 14. https:\/\/doi.org\/10.1186\/1471-2407-14-292","journal-title":"BMC Cancer"},{"key":"2638_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2015.12.004","volume":"37","author":"I Orsolic","year":"2016","unstructured":"Orsolic I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S (2016) The relationship between the nucleolus and cancer: current evidence and emerging paradigms. Semin Cancer Biol 37:36\u201350","journal-title":"Semin Cancer Biol"},{"key":"2638_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/195209","volume":"2011","author":"MS Lindstrom","year":"2011","unstructured":"Lindstrom MS (2011) NPM1\/B23: a multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int 2011","journal-title":"Biochem Res Int"},{"key":"2638_CR35","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS (2022) Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res 82:2344\u20132353","journal-title":"Cancer Res"},{"key":"2638_CR36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.32600","volume":"126","author":"JM Santiago-O'Farrill","year":"2020","unstructured":"Santiago-O\u2019Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE et al (2020) Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer 126:894\u2013907. https:\/\/doi.org\/10.1002\/cncr.32600","journal-title":"Cancer"},{"key":"2638_CR37","doi-asserted-by":"publisher","unstructured":"Weng YS, Chiang IT, Tsai JJ, Liu YC, Hsu FT (2022) Lenvatinib synergistically promotes radiation therapy in hepatocellular carcinoma by inhibiting Src\/STAT3\/NF-kappaB-mediated epithelial-mesenchymal transition and metastasis. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.060","DOI":"10.1016\/j.ijrobp.2022.09.060"},{"key":"2638_CR38","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/CMAR.S188316","volume":"11","author":"M Capozzi","year":"2019","unstructured":"Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S (2019) Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res 11:3847\u20133860. https:\/\/doi.org\/10.2147\/CMAR.S188316","journal-title":"Cancer Manag Res"},{"key":"2638_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4718-6","volume":"18","author":"S Chen","year":"2018","unstructured":"Chen S, He H, Wang Y, Liu L, Liu Y, You H, Dong Y, Lyu J (2018) Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis. BMC Cancer 18. https:\/\/doi.org\/10.1186\/s12885-018-4718-6","journal-title":"BMC Cancer"},{"key":"2638_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13125-5","volume":"24","author":"A Chao","year":"2024","unstructured":"Chao A, Huang CY, Yu W, Lin CY, Lin H, Chao AS, Lin CT, Chou HH, Huang KG, Huang HJ et al (2024) Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma. BMC Cancer 24. https:\/\/doi.org\/10.1186\/s12885-024-13125-5","journal-title":"BMC Cancer"},{"key":"2638_CR41","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-21-1733","volume":"28","author":"JM Lee","year":"2022","unstructured":"Lee JM, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ES et al (2022) Cediranib in combination with olaparib in patients without a germline BRCA1\/2 mutation and with recurrent platinum-resistant ovarian cancer: phase IIb CONCERTO trial. Clin Cancer Res 28:4186\u20134193. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1733","journal-title":"Clin Cancer Res"},{"key":"2638_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ygyno.2022.01.015","volume":"164","author":"N Colombo","year":"2022","unstructured":"Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R et al (2022) Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer. Gynecol Oncol 164:505\u2013513. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.015","journal-title":"Gynecol Oncol"},{"key":"2638_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101767","volume":"54","author":"G Liu","year":"2022","unstructured":"Liu G, Feng Y, Li J, Deng T, Yin A, Yan L, Zheng M, Xiong Y, Li J, Huang Y et al (2022) A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: efficacy and safety results from the phase II, multi-center ANNIE study. EClinicalMedicine 54. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101767","journal-title":"EClinicalMedicine"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02638-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02638-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:12:27Z","timestamp":1769217147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02638-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2638"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02638-0","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (IRB No.: 201702257B0) was approved by Institute Review Board (IRB) of Chang Gung Memorial Hospital (CGMH). All animal procedures were approved by the Animal Care and Use Committee of the Institutional Review Board of the Chang Gung Memorial Hospital (202102047B0, 202200254B0, 201702257B0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Chyong-Huey Lai received a fee from Novartis for a position on the DMC of CBYL719K12301 EPIK-O and research grants from MSD and MaNGO. Alice L Yu serves on the board of director of the OPKO Health, and owns stocks of Acepodia Biotech, OPKO Health and OBI Pharma. Angel Chao received research grants form AstraZeneca and Seagen. The other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"33"}}